Zacks Investment Research upgraded shares of Sientra (NASDAQ:SIEN) from a sell rating to a hold rating in a research report released on Wednesday, Zacks.com reports.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
A number of other research analysts have also weighed in on SIEN. Wells Fargo & Co began coverage on Sientra in a research report on Thursday, March 14th. They set a market perform rating and a $9.00 price objective for the company. Maxim Group reaffirmed a buy rating and set a $20.00 price objective on shares of Sientra in a research report on Monday, February 11th. ValuEngine lowered Sientra from a strong-buy rating to a buy rating in a research report on Thursday, January 24th. BidaskClub lowered Sientra from a sell rating to a strong sell rating in a research report on Tuesday, December 18th. Finally, Stifel Nicolaus reduced their price objective on Sientra from $19.00 to $16.00 and set a buy rating for the company in a research report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $20.44.
SIEN stock opened at $7.52 on Wednesday. Sientra has a twelve month low of $7.10 and a twelve month high of $26.79. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 1.75. The company has a market cap of $219.67 million, a P/E ratio of -2.31 and a beta of -0.08.
Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Tuesday, March 12th. The medical instruments supplier reported ($0.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.19). Sientra had a negative net margin of 121.28% and a negative return on equity of 123.51%. The company had revenue of $19.02 million for the quarter, compared to the consensus estimate of $18.87 million. Equities research analysts forecast that Sientra will post -2.84 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of SIEN. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Sientra during the 4th quarter valued at $29,000. Great West Life Assurance Co. Can purchased a new stake in Sientra during the 4th quarter valued at $64,000. Metropolitan Life Insurance Co. NY boosted its stake in Sientra by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 6,397 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Sientra during the 4th quarter valued at $135,000. Finally, HRT Financial LLC purchased a new stake in Sientra during the 4th quarter valued at $157,000. Institutional investors and hedge funds own 90.81% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
See Also: Why do corrections happen?
Get a free copy of the Zacks research report on Sientra (SIEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.